XERIS BIOPHARMA HOLDINGS, INC. Cash and Restricted Cash
XERIS BIOPHARMA HOLDINGS, INC. (XERS) had Cash and Restricted Cash of $125.77 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $125.77M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $115.77M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $115.06M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $95.62M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $125.77M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $115.77M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $115.06M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $95.62M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $63.41M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $62.56M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $75.74M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $63.35M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $61.83M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $66.92M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $71.67M 10-K · filed 2026-03-02 |
| 2023-09-30 | $50.57M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $50.60M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $55.33M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $126.31M 10-K · filed 2026-03-02 |
| 2022-09-30 | $84.11M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $95.34M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $103.77M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $67.27M 10-K · filed 2025-03-06 |
| 2021-09-30 | $59.49M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $63.60M 10-Q · filed 2022-08-10 |
| 2021-03-31 | $66.60M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $37.60M 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |